$42.89
-0.79[-1.81%]
Last update: 9:30AM Get Real Time Here
Crinetics Pharmaceuticals
(NASDAQ:CRNX)Crinetics Pharmaceuticals Stock (NASDAQ:CRNX), Analyst Ratings, Price Targets, Predictions
Crinetics Pharmaceuticals Inc has a consensus price target of $54.92, established from looking at the 48 latest analyst ratings. The last 3 analyst ratings were released from JMP Securities, Oppenheimer, and JMP Securities on March 28, 2024, March 20, 2024, and March 20, 2024. With an average price target of $71.67 between JMP Securities, Oppenheimer, and JMP Securities, there's an implied 65.19% upside for Crinetics Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
Oppenheimer
HC Wainwright & Co.
JonesTrading
Citigroup
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Crinetics Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/28/2024 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 84.4% | JMP Securities | Jonathan Wolleben | → $80 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/20/2024 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 26.77% | Oppenheimer | Leland Gershell | $54 → $55 | Maintains | Outperform | Get Alert |
| 03/20/2024 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 84.4% | JMP Securities | Jonathan Wolleben | $60 → $80 | Maintains | Market Outperform | Get Alert |
| 03/20/2024 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 38.3% | HC Wainwright & Co. | Douglas Tsao | $50 → $60 | Maintains | Buy | Get Alert |
| 03/20/2024 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 29.08% | JonesTrading | Lina Kaminski | $52 → $56 | Maintains | Buy | Get Alert |
| 03/19/2024 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 15.25% | HC Wainwright & Co. | Douglas Tsao | → $50 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2024 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 24.47% | Oppenheimer | Leland Gershell | $48 → $54 | Reiterates | Outperform → Outperform | Get Alert |
| 03/13/2024 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 15.25% | HC Wainwright & Co. | Douglas Tsao | → $50 | Reiterates | Buy → Buy | Get Alert |
| 03/08/2024 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 15.25% | HC Wainwright & Co. | Douglas Tsao | $42 → $50 | Maintains | Buy | Get Alert |
| 03/06/2024 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 56.74% | Citigroup | David Lebovitz | → $68 | Initiates | → Buy | Get Alert |
| 03/04/2024 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 49.82% | Cantor Fitzgerald | Josh Schimmer | $50 → $65 | Maintains | Overweight | Get Alert |
| 02/29/2024 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 38.3% | JMP Securities | Jonathan Wolleben | $50 → $60 | Maintains | Market Outperform | Get Alert |
| 02/29/2024 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 10.64% | Oppenheimer | Leland Gershell | $46 → $48 | Maintains | Outperform | Get Alert |
| 02/29/2024 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 19.86% | Baird | Brian Skorney | $45 → $52 | Maintains | Outperform | Get Alert |
| 02/02/2024 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 15.25% | Cantor Fitzgerald | Josh Schimmer | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 01/16/2024 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 15.25% | Morgan Stanley | Jeffrey Hung | → $50 | Initiates | → Overweight | Get Alert |
| 12/19/2023 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 15.25% | Cantor Fitzgerald | Josh Schimmer | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 12/19/2023 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | -3.19% | HC Wainwright & Co. | Douglas Tsao | → $42 | Reiterates | Buy → Buy | Get Alert |
| 12/04/2023 | CRNX | Buy Now | Crinetics Pharmaceuticals | $43.38 | 15.25% | Cantor Fitzgerald | Josh Schimmer | → $50 | Reiterates | Overweight → Overweight | Get Alert |
FAQ
What is the target price for Crinetics Pharmaceuticals (CRNX)?
The latest price target for Crinetics Pharmaceuticals (NASDAQ: CRNX) was reported by JMP Securities on March 28, 2024. The analyst firm set a price target for $80.00 expecting CRNX to rise to within 12 months (a possible 86.52% upside). 38 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Crinetics Pharmaceuticals (CRNX)?
The latest analyst rating for Crinetics Pharmaceuticals (NASDAQ: CRNX) was provided by JMP Securities, and Crinetics Pharmaceuticals reiterated their market outperform rating.
When was the last upgrade for Crinetics Pharmaceuticals (CRNX)?
The last upgrade for Crinetics Pharmaceuticals Inc happened on June 18, 2021 when JP Morgan raised their price target to $28. JP Morgan previously had a neutral for Crinetics Pharmaceuticals Inc.
When was the last downgrade for Crinetics Pharmaceuticals (CRNX)?
There is no last downgrade for Crinetics Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Crinetics Pharmaceuticals (CRNX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Crinetics Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Crinetics Pharmaceuticals was filed on March 28, 2024 so you should expect the next rating to be made available sometime around March 28, 2025.
Is the Analyst Rating Crinetics Pharmaceuticals (CRNX) correct?
While ratings are subjective and will change, the latest Crinetics Pharmaceuticals (CRNX) rating was a reiterated with a price target of $0.00 to $80.00. The current price Crinetics Pharmaceuticals (CRNX) is trading at is $42.89, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.